Reyes De Torres Chacon

Reyes De Torres Chacon

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Atherosclerosis Plus
Verified
Journal Article
Open access
MBMarina Blanco-Ruiz
Marina Blanco-Ruiz
LALaura Amaya-Pascasio
Laura Amaya-Pascasio
RCReyes De Torres Chacon
Reyes De Torres Chacon
MSMaría Josefa Álvarez Soria
María Josefa Álvarez Soria
AAAntonio Arjona-Padillo
Antonio Arjona-Padillo
Patricia Martinez-SanchezPatricia Martinez-Sanchez
Patricia Martinez-Sanchez
The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials. However, few studies of routine clinical practice have been conducted to analyse and compare the efficacy and safety of the two drugs. Retrospective observational study of patients treated with a PCSK9 inhibitor in five hospitals in Andalusia (southern Spain). Baseline demographic and clinical data, LDL-cholesterol levels and the occurrence of MACEs during the follow-up period were recorded. A total of 141 patients were included in the study: 90 were treated with alirocumab and 51 with evolocumab. The patients’ mean age (IQR) was 58 (11) years and 58 (41%) were women. The most frequent concomitant medications were statins, 94 (66.7%), followed by antiplatelet therapy (66%) and ezetimibe (65.2%). The median (IQR) follow-up period was 18 (18) months, with 18 (24) for alirocumab and 11 (18) for evolocumab. At the six-month follow-up visit, LDL-cholesterol values had decreased to pre-treatment levels and remained significantly decreased (p < 0.05) over time, for both drugs, and a greater reduction was achieved in patients with established cardiovascular disease and concomitant treatment with statins. With respect to adverse effects, there were nine MACEs (6.4%), of which seven were with alirocumab (7.8%) and two with evolocumab (3.9%) (p NS). Other adverse effects (9.2%) included local erythema (3.5%), muscle cramps (2.1%), respiratory symptoms (2.1%) and asthaenia (1.4%). The efficacy and safety of alirocumab and evolocumab in routine clinical practice are consistent with the findings of the pivotal clinical trials.

13 December 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
ANAna M. Nájar
Ana M. Nájar
CACristina López Azcárate
Cristina López Azcárate
CRCarmen Domínguez Ruiz
Carmen Domínguez Ruiz
DNDavid Núñez-Jurado
David Núñez-Jurado
RCReyes De Torres Chacon
Reyes De Torres Chacon
SPSoledad Pérez-Sánchez
Soledad Pérez-Sánchez
Transient ischemic attack (TIA) is a well-established risk factor for future strokes, making interventions that target recovery and vascular risk crucial. This study aimed to assess the safety and clinical effects of a polyphenol-rich Salicornia ramosissima extract in post-TIA patients. A randomized, triple-blind, placebo-controlled trial was conducted with participants who had a history of TIA or minor stroke and who received 1 g of Salicornia extract or placebo over 11 months. Biochemical analyses, neuropsychological assessments (MOCA test), and gait and aerobic performance tests were conducted at the beginning and the end of the study. A total of 118 individuals were screened, with 80 finally included. Importantly, no significant adverse events were reported throughout the study. A neurological analysis showed an improvement in MOCA scores in patients treated with the Salicornia extract for 11 months. The treatment did not affect spatiotemporal gait parameters, but it significantly reduced blood pressure at baseline and after the aerobic performance test. Biochemically, both groups exhibited mild hyperhomocysteinemia at baseline; however, Salicornia treatment significantly lowered homocysteine levels, bringing them within the normal range. These findings highlight the safety of the Salicornia extract in patients at a high cerebrovascular risk and suggest it as a potential therapeutic option for managing vascular risk factors, such as hyperhomocysteinemia and hypertension. However, further studies are required to confirm the underlying mechanisms and explore broader clinical applications.

6 May 2026 in European Stroke Journal
Verified
Journal Article
Open access
SPSoledad Pérez-Sánchez
Soledad Pérez-Sánchez
CRCarmen del Río
Carmen del Río
DNDavid Núñez-Jurado
David Núñez-Jurado
ANAna María Najar
Ana María Najar
RORafael F Ocete
Rafael F Ocete
JMJoan Montaner
Joan Montaner
Introduction: Cerebral small vessel disease is a major cause of lacunar stroke and vascular cognitive impairment, for which effective disease-modifying treatments are lacking. Polyphenols have shown neurovascular and neuroprotective effects in experimental models. We conducted a randomised pilot trial primarily to evaluate the safety and tolerability of a polyphenol-rich Salicornia extract in patients with lacunar stroke. Patients and methods: In this randomised, double-blind, placebo-controlled, parallel-group pilot trial, patients with recent lacunar stroke received either 1 g/day of a polyphenol-rich Salicornia extract or placebo for 12 months (ClinicalTrials.gov NCT06076122). The primary endpoint was safety and tolerability. Secondary exploratory outcomes included cognitive performance (Montreal Cognitive Assessment), physical function (6-min walk test and gait speed), biochemical parameters, ambulatory blood pressure and neuroimaging markers, assessed at baseline, 6 months and study completion. Results: Seventy-one participants were randomised (40 to placebo and 31 to Salicornia extract). No treatment-related serious adverse events were observed. Exploratory analyses of secondary outcomes suggested possible between-group differences in some cognitive and physical measures. At 12 months, adjusted MoCA scores were higher in the Salicornia group than in the placebo group (adjusted mean difference 2.22 points; 95% CI, 0.08–4.36; P = .042), although cognitive data were available for only 22/40 placebo-treated and 19/31 Salicornia-treated participants. Apparent differences were also observed in some physical function measures during follow-up. In biochemical parameters, a reduction in homocysteine levels was observed in both groups. No relevant between-group differences were detected in neuroimaging markers during follow-up. These secondary findings should be interpreted as exploratory only and not as evidence of efficacy. Discussion: Any apparent differences in secondary exploratory cognitive, functional and biochemical outcomes should be interpreted cautiously because of baseline imbalances, small sample size and substantial missing follow-up data. These findings should be considered hypothesis-generating only and not as evidence of efficacy. Conclusions: Long-term supplementation with a polyphenol-rich S ramosissima extract showed an acceptable safety profile in patients with lacunar stroke, although tolerability should be interpreted cautiously given the withdrawal rate. Larger, adequately powered trials are needed to determine whether these preliminary findings represent true treatment effects.

1 January 2021 in Revista De Neurologia
Verified
Journal Article
Closed access
SSSoledad Pérez Sánchez
Soledad Pérez Sánchez
APAna Barragán Prieto
Ana Barragán Prieto
JMJosé Antonio Sánchez Miura
José Antonio Sánchez Miura
AMAna María Domínguez Mayoral
Ana María Domínguez Mayoral
RCReyes De Torres Chacon
Reyes De Torres Chacon
JMJoan Montaner
Joan Montaner
Minor strokes are considered to be those that present with few symptoms, although up to 40% of them entail long-term disability. The rate of thrombolysis in these patients is also lower than in other strokes. The aim of this study is to explore whether there are any differences in intravenous thrombolysis care times in minor strokes. We conducted a retrospective review of strokes treated with intravenous thrombolysis at our centre and a comparative analysis of the care times in minor strokes and in the other types. Longer times were found in minor strokes in terms of door-to-CT scan and door-to-needle time. This was not the case, however, for the time from the onset of symptoms to arrival at the hospital. The presence of few symptoms in minor strokes can make them difficult to recognise and could be a reason for delaying treatment. Training among staff caring for these patients is essential to improve this aspect.

20 May 2026 in Neurología
Verified
Journal Article
Open access
MFM. Freijo-Guerrero
M. Freijo-Guerrero
PCP. Cardona
P. Cardona
MCMar Castellanos
Mar Castellanos
RCReyes De Torres Chacon
Reyes De Torres Chacon
AGA. Gil-Núñez
A. Gil-Núñez
JMJaime Masjuan
Jaime Masjuan